Stereotaxis (STXS) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Stereotaxis is projected to report Q1 2026 results after the close on May 12, 2026, with analysts expecting ($0.05) EPS and about $8.62 million in revenue; the earnings call is scheduled for 4:30 PM ET.
• In the prior quarter the company posted ($0.06) EPS (meeting estimates) and $8.64M revenue (below estimates), carries a negative net margin and negative return on equity, and analysts see $0 EPS for the current and next fiscal year.
• Stereotaxis makes the Niobe robotic magnetic navigation system for cardiac electrophysiology; its stock trades near $1.96 with a market cap of roughly $190.6M and about 45% institutional ownership.

Stereotaxis (NYSEAMERICAN:STXS - Get Free Report) is projected to announce its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $8.62 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Stereotaxis (NYSEAMERICAN:STXS - Get Free Report) last posted its earnings results on Monday, March 9th. The company reported ($0.06) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.06). Stereotaxis had a negative return on equity of 291.99% and a negative net margin of 66.85%.The business had revenue of $8.64 million for the quarter, compared to analyst estimates of $9.24 million. On average, analysts expect Stereotaxis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Stereotaxis Price Performance

Stereotaxis stock traded up $0.06 during mid-day trading on Tuesday, hitting $1.96. 70,041 shares of the company's stock traded hands, compared to its average volume of 481,004. The firm has a 50 day simple moving average of $1.95 and a two-hundred day simple moving average of $2.30. Stereotaxis has a fifty-two week low of $1.74 and a fifty-two week high of $3.59. The stock has a market cap of $190.57 million, a price-to-earnings ratio of -7.78 and a beta of 1.34.

Institutional Trading of Stereotaxis

A number of hedge funds have recently modified their holdings of STXS. Vanguard Group Inc. grew its stake in Stereotaxis by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company's stock valued at $10,702,000 after buying an additional 138,482 shares during the last quarter. Arbiter Partners Capital Management LLC boosted its holdings in shares of Stereotaxis by 1.1% during the fourth quarter. Arbiter Partners Capital Management LLC now owns 2,883,856 shares of the company's stock worth $6,633,000 after acquiring an additional 30,000 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Stereotaxis by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 1,565,182 shares of the company's stock worth $3,601,000 after acquiring an additional 55,491 shares during the period. State Street Corp grew its position in shares of Stereotaxis by 11.4% in the fourth quarter. State Street Corp now owns 891,886 shares of the company's stock valued at $2,051,000 after purchasing an additional 91,453 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in shares of Stereotaxis during the fourth quarter worth approximately $1,380,000. Institutional investors and hedge funds own 45.35% of the company's stock.

About Stereotaxis

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company's flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.